Breaking News Instant updates and real-time market news.

RIGL

Rigel Pharmaceuticals

$3.35

(0.00%)

15:59
04/12/18
04/12
15:59
04/12/18
15:59

Rigel says website corrected, FDA continuing review of fostamatinib NDA

Rigel Pharmaceuticals reported that due to an error by the external host of its investor relations website, inaccurate information was displayed regarding the U.S. Food and Drug Administration's review of the New Drug Application, or NDA, for fostamatinib for the treatment of adult patients with chronic immune thrombocytopenia. "The website has been corrected. The FDA is continuing its review of the NDA and the Prescription Drug User Fee Act action date is April 17, 2018," the company stated.

  • 17

    Apr

RIGL Rigel Pharmaceuticals
$3.35

(0.00%)

04/03/18
JEFF
04/03/18
NO CHANGE
Target $5
JEFF
Buy
Rigel selloff on IgAN trial miss overdone, says Jefferies
Jefferies analyst Eun Yang called the fact that Rigel Pharmaceuticals' Phase 2 trial evaluating fostamatinib in IgAN failed to meet its primary endpoint "somewhat disappointing," but also said the news does not change his valuation or view on the approvability in patients with chronic or persistent immune thrombocytopenia. The analyst, who said the company is "completely optimistic" for timely approval of fostamatinib in the ITP indication by the PDUFA date of April 17, keeps a Buy rating and $5 price target on Rigel shares, calling today's selloff "overdone."
04/03/18
HCWC
04/03/18
NO CHANGE
Target $6.7
HCWC
Buy
H.C. Wainwright says Rigel's 'small setback' a buying opportunity ahead of PDUFA
H.C. Wainwright analyst Joseph Pantginis called news that Rigel Pharmaceuticals' Phase 2 study of fostamatinib in patients with IgA nephropathy did not meet its primary endpoint a "small setback" for the company and an opportunity for investors. He believes today's selling pressure is an overreaction, adding that "brighter skies may be tomorrow, almost literally," with the company's PDUFA date for fostamatinib in ITP coming on April 17. Pantginis reiterates a Buy rating on Rigel and trimmed his price target on the stock to $6.70 from $7.
04/04/18
JEFF
04/04/18
NO CHANGE
Target $5
JEFF
Buy
Rigel selloff yesterday on failed study overdone, says Jefferies
Jefferies analyst Eun Yang says that while yesterday's Phase 2 trial results in IgA nephropathy, fostamatinib's third indication, is "somewhat disappointing," it does not change her valuation or upcoming approvability in first indication immune thrombocytopenic purpura. The analyst views the selloff yesterday in shares of Rigel Pharmaceuticals as overdone. She believes the failed study has no bearing on the approval in ITP, which has an FDA action date of April 17. Yang reiterates a Buy rating on Rigel with a $5 price target.
04/09/18
JPMS
04/09/18
NO CHANGE
JPMS
Overweight
Rigel Pharmaceuticals shares can rally 80% on FDA approval, says JPMorgan
JPMorgan analyst Anupam Rama continues to see a favorable risk/reward profile on Rigel Pharmaceuticals heading into the April 17 FDA action date for Tavalisse in immune thrombocytopenia. The analyst sees a "high probability" of approval for Tavalisse and 50%-80% share upside on the news, "assuming no major surprises in the label." The approval is setting up to be a "true binary event," with potential share downside in the 65%-80% range, Rama tells investors in a research note. He keeps an Overweight rating on Rigel shares.

TODAY'S FREE FLY STORIES

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:55
08/14/18
08/14
16:55
08/14/18
16:55
Hot Stocks
LRAD Corporation says 'well positioned to achieve record fiscal year revenues' »

"LRAD is in a much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:54
08/14/18
08/14
16:54
08/14/18
16:54
Hot Stocks
Breaking Hot Stocks news story on LRAD Corporation »

LRAD Corporation reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

LRAD

LRAD Corporation

$2.83

0.02 (0.71%)

16:53
08/14/18
08/14
16:53
08/14/18
16:53
Earnings
LRAD Corporation reports Q3 EPS 0c, one estimate 0c »

Reports Q3 revenue $7.5M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 23

    Aug

CDNA

CareDx

$16.87

-0.13 (-0.76%)

16:50
08/14/18
08/14
16:50
08/14/18
16:50
Hot Stocks
CareDx CFO Michael Brian Bell sells 12,500 shares of company stock »

CareDx CFO Michael Brian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

VNDA

Vanda Pharmaceuticals

$21.60

0.15 (0.70%)

16:46
08/14/18
08/14
16:46
08/14/18
16:46
Hot Stocks
Vanda Pharmaceuticals wins denial of petition for rehearing on Fanapt »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$193.08

-1.03 (-0.53%)

16:45
08/14/18
08/14
16:45
08/14/18
16:45
Recommendations
Home Depot analyst commentary  »

Home Depot underlying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FANG

Diamondback Energy

$133.75

1.84 (1.39%)

16:45
08/14/18
08/14
16:45
08/14/18
16:45
Hot Stocks
Breaking Hot Stocks news story on Diamondback Energy »

Diamondback Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$98.41

1.32 (1.36%)

, UTX

United Technologies

$132.40

0.23 (0.17%)

16:42
08/14/18
08/14
16:42
08/14/18
16:42
Hot Stocks
Pershing Square adds Lowe's, cuts stake in ADP »

Bill Ackman's…

LOW

Lowe's

$98.41

1.32 (1.36%)

UTX

United Technologies

$132.40

0.23 (0.17%)

MDLZ

Mondelez

$41.87

-0.03 (-0.07%)

ADP

ADP

$141.17

1.48 (1.06%)

QSR

Restaurant Brands

$62.20

0.355 (0.57%)

CMG

Chipotle

$493.33

8.97 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 22

    Aug

  • 07

    Sep

  • 11

    Sep

  • 12

    Sep

  • 24

    Sep

DXC

DXC Technology

$86.56

2.02 (2.39%)

16:41
08/14/18
08/14
16:41
08/14/18
16:41
Hot Stocks
DXC Technology awarded $400M contract by Wisconsin DHS »

The Wisconsin Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

16:39
08/14/18
08/14
16:39
08/14/18
16:39
General news
API crude inventories for week of August 10 »

API reports that crude…

CSOD

Cornerstone OnDemand

$52.59

0.48 (0.92%)

16:35
08/14/18
08/14
16:35
08/14/18
16:35
Recommendations
Cornerstone OnDemand analyst commentary  »

Cornerstone OnDemand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 04

    Sep

  • 06

    Sep

  • 07

    Sep

  • 12

    Sep

  • 12

    Sep

ATNM

Actinium Pharmaceuticals

$0.62

0.003 (0.49%)

16:34
08/14/18
08/14
16:34
08/14/18
16:34
Conference/Events
Actinium Pharmaceuticals to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 04

    Sep

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

16:34
08/14/18
08/14
16:34
08/14/18
16:34
Earnings
Perspecta sees FY18 pro forma revenue $4.150B-$4.250B, consensus $4.2B »

Sees FY19 adjusted EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

FCN

FTI Consulting

$80.32

0.33 (0.41%)

16:33
08/14/18
08/14
16:33
08/14/18
16:33
Syndicate
Breaking Syndicate news story on FTI Consulting »

FTI Consulting files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRSP

Perspecta

$21.64

-0.31 (-1.41%)

16:32
08/14/18
08/14
16:32
08/14/18
16:32
Hot Stocks
Perspecta reports Q1 adjusted EPS 54c, consensus 46c »

Reports Q1 revenue $793M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

SBBP

Strongbridge Biopharma

$6.25

0.3 (5.04%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Syndicate
Strongbridge Biopharma files to sell 9M ordinary shares »

Cowen and Stifel are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HWC

Hancock Whitney

$51.40

0.6 (1.18%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Hancock Whitney names Christopher Ziluca as new Chief Credit Officer »

Hancock Whitney has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATRI

Atrion

$656.00

9 (1.39%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Atrion increases quarterly cash dividend by 13% »

Atrion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIK

Tel-Instrument

$2.60

(0.00%)

16:31
08/14/18
08/14
16:31
08/14/18
16:31
Hot Stocks
Tel-Instrument receives NYSE non-compliance letter »

Tel Instrument…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/14/18
08/14
16:30
08/14/18
16:30
Options
Preliminary option volume of 16.1M today »

Preliminary option volume…

DLPN

Dolphin Entertainment

$2.96

(0.00%)

16:29
08/14/18
08/14
16:29
08/14/18
16:29
Earnings
Dolphin Entertainment reports Q2 EPS (1c), consensus 2c »

Reports Q2 revenue $5.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

BK

BNY Mellon

$50.97

0.825 (1.65%)

, GE

General Electric

$12.35

-0.09 (-0.72%)

16:29
08/14/18
08/14
16:29
08/14/18
16:29
Hot Stocks
Trian Fund boosts BNY Mellon, lowers stake in Wendy's »

Nelson Peltz's Trian…

BK

BNY Mellon

$50.97

0.825 (1.65%)

GE

General Electric

$12.35

-0.09 (-0.72%)

MDLZ

Mondelez

$41.87

-0.03 (-0.07%)

WEN

Wendy's

$17.84

0.48 (2.77%)

SYY

Sysco

$74.19

1.47 (2.02%)

PG

Procter & Gamble

$81.31

-0.21 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 07

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

VRAY

ViewRay

$9.89

-0.01 (-0.10%)

16:28
08/14/18
08/14
16:28
08/14/18
16:28
Syndicate
ViewRay files to sell $125M of common stock »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

LMB

Limbach Holding

$10.70

0.11 (1.04%)

16:26
08/14/18
08/14
16:26
08/14/18
16:26
Earnings
Limbach Holding raises FY18 revenue view to $530-$550M from $520M-$540M »

Consensus $527.77M. Now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

MRSN

Mersana Therapeutics

$12.75

0.04 (0.31%)

16:26
08/14/18
08/14
16:26
08/14/18
16:26
Earnings
Mersana Therapeutics reports Q2 EPS (54c), consensus (58c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 15

    Aug

  • 04

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.